Antigen receptor found on the T cell membrane that can efficiently recognize antigens that arise on the surface of a cell or from within a cell. NTLA-5001, which is Intellia’s first investigational engineered T cell therapy and is wholly owned, utilizes a TCR-directed approach to target the WT1 intracellular antigen for the treatment of AML.